Clinical Assessment of Spinal Muscular Atrophy Type II and III (SMA Europe)

Clinical Assessment of Spinal Muscular Atrophy Type II and III

The aim of this project is to establish a network of clinical teams including the major neuromuscular centers in Europe.

We plan to work together to find the best common outcome measures for the following multicenter therapeutic trials.

16 patients (6 ambulant and 10 non ambulant), affected by type II and type III SMA will be enrolled and assessed at baseline and 6 and 12 months later. Non ambulant patients will be assessed using the modified version of the Hammersmith Motor Functional Scale while ambulant patients will be assessed using the extended module of the Hammersmith Motor Functional Scale and timed items, the 6 minute walk and a step activity monitor. All patients will also be assessed using the Motor Function Measure (MFM), that covers the whole range of activities for both ambulant and non ambulant patients. All measures will undergo a process of validation including inter observer reliability. This information will be most valuable for any future trial and will make the groups involved ready to participate to future collaborative studies saving a lot of time on the preliminary aspects (validation, reliability, training) that will be fulfilled by the present study. The study will also provide natural history data for a 12 month period on patients with SMA II and III.

Inclusion Criteria for ambulant patients:

• age between 30 months and 24 years
• documented SMA diagnosis by genetic tests; Each should also have the determination of the SMN2 copy number
• able to walk 10 meters without support
• subject who signed an informed consent- subject affiliated to a social security system

Inclusion Criteria non ambulant patients:

• documented diagnosis of SMA by genetic tests
• not able to walk 10 meters without support
• subject affiliated to a social security system
• subject who signed an informed consent

Exclusion Criteria:

• Patient who are currently involved in other clinical trials
• severe intellectual impairment limiting the comprehension of the demanded tasks
• acute neurologic, inflammatory, infectious, endocrine, orthopedic disease in the month preceding the inclusion
• chronic neurologic (besides SMA), inflammatory, infectious, endocrine, orthopedic disease which are not a natural consequence of SMA
• spinal surgery scheduled 6 months before or within 12 months after enrollment
• pregnant women